Quote:Coya Therapeutics has low dose IL-2 phase 2 results in Alzheimer's to be presented end of October. Trial funding from Gates Foundation and Alzheimer's Association.
Hmm... I wonder if Mr. Collin is aware of leronlimab.
If Howard Berman is aware of leronlimab he should be very worried.
GLP-1 antagonists could lower inflammation to some extent due to loss of body fat, however it would do nothing for any other contributing factors. It can slow decline although not halt it.
Quote:The randomized, double-blind, placebo-controlled Evaluating the Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimer’s Disease (ELAD) trial led by Prof. Paul Edison, M.D., Ph.D. , professor of science from Imperial College London, included 204 patients with mild Alzheimer’s disease seen at 24 clinics throughout the United Kingdom.
Edison added that those in the study who received liraglutide had nearly 50% less volume loss in several areas of the brain, including frontal, temporal, parietal and total gray matter, as measured by MRI. These areas are responsible for a variety of critical functions that often are affected by Alzheimer’s disease, including memory, language and decision-making.
Researchers also conducted cognitive testing in the patients — before treatment and at 24 and 52 weeks. Although the study was not powered to assess cognitive changes, researchers found that patients who received liraglutide had an 18% slower decline in cognitive function in a year compared to those who got the placebo.
Cognitive function was calculated as a composite score of 18 different tests of memory, comprehension, language and spatial orientation (ADAS EXEC z score). For those in the study who completed 52 weeks of treatment (treatment n=79, placebo n=87), those taking the drug saw a statistically significant slowing of cognitive decline (p<0.01).
https://aaic.alz.org/releases-2024/glp-drug-l...entia.asp#
Coya wants to use Low Dose IL-2 for treatment, Collin suggests combining GLP-1 with CAR-Treg cells.
Both treatments would significantly increase the amount of T-regulatory cells which inhibit inflammation. The problem that could arise is it does so by suppressing immune response which could lead to significant problems if the patient is presented with any immune challenge from viruses etc. The other problem I see is that immune suppression and the ability of Tregs to protect cancer cells means that precancerous cells could be more likely to turn into cancer.
18
